Embedded Files
The Utility of Frequency-Modulated Electromagnetic Neural Stimulation (FREMS) as a Third Line Treatment in Patients with Painful Diabetes-Related Peripheral Neuropathy: A Randomised Controlled Trial
The Utility of Frequency-Modulated Electromagnetic Neural Stimulation (FREMS) as a Third Line Treatment in Patients with Painful Diabetes-Related Peripheral Neuropathy: A Randomised Controlled Trial
Updated 19 February 2025
Diabetes (DM) is very common in the UK and globally and is a major health care challenge for the NHS. Painful Diabetes-related Peripheral Neuropathy (PDPN) is a serious complication affecting 20-26% of patients with DM. The mainstay of treatment is pharmacotherapy, although there is moderate evidence for the efficacy of the recommended drug treatments available, often leading to opioid use. Side effects and drug withdrawal are common. There is a clear gap in the treatment pathway of patients with PDPN regarding a safe, non-invasive, clinically effective and cost effective third line treatment that is safe with an acceptable safety/side-effect profile. Treatment with a Frequency-Modulated Electromagnetic Neural Stimulation (FREMS) machine may be able to address this gap: FREMS may offer lasting and non-invasive pain relief for PDPN. FREMS treatment may have the potential to reduce the need for pharmacotherapy (particularly opioids) and its associated risks. FREMS-PDPN aims to evaluate the clinical and cost-effectiveness of FREMS for adults with PDPN.
EMIS Web Resources
EMIS Web Resources
EMIS Search (12/08/2024)
Disclaimer:
Please note the resources provided are designed to assist with the identification of potentially suitable patients and to appropriately code these patient if required.
These resources have been developed based on the criteria provided by the relevant study team and whilst every effort has been made to make them universally implementable they rely on read codes and the data stored in the individual practice's clinical system. These resources are intended to assist with identification but should be used in conjunction with clinical oversight and a clear understanding of the study parameters.
While we endeavour to keep the information, tools and resources provided up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the tools provided for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of the tools provided.
Page updated
Report abuse